Effect of privatization of the drug distribution system on drug prices in Malaysia

Z. D. Babar, M. I.M. Izham

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Previous studies on anti-infective and cardiovascular drugs have shown extraordinary price increases following privatization of the Malaysian drug distribution system. Therefore, it was felt that there was a need to undertake a full-scale study to evaluate the effect of privatization of the Malaysian drug distribution system on drug prices. Objectives: To compare pre-privatization drug prices with post-privatization drug prices, and to compare the prices with international reference prices (IRPs). Methods: Five hundred and sixty-four drugs were listed in price lists for 1994, 1995-1996, 1997-2000 and 2001-2003. The 1994 data were taken as the pre-privatization prices, and all other lists were considered to be post-privatization prices. The pre-privatization prices (1994) were compared with those in 1995-1996. The prices in 1995-1996 were compared with those in 1997-2000, and the 1997-2000 prices were compared with those in 2001-2003. Furthermore, the 2001-2003 prices were compared with the median IRPs taken from Management Sciences for Health. Results: The prices increased by 10.42% in 1995-1996, decreased by 3.37% in 1997-2000, and increased by 64.04% in 2001-2003. The increase in prices does not follow any pricing formula but is influenced by free market principles. The commonly used generic drugs showed enormously higher prices compared with the IRPs. Conclusion: Some of the prices increased several hundred-fold compared with the previous year, showing that no pricing formula has been followed. Increasing prices over the years may lead to higher expenditures and a hurdle to drug accessibility. A rational pricing structure is needed for transparent pricing, and government involvement and the formation of a medicine pricing policy seems vital.

Original languageEnglish
Pages (from-to)523-533
Number of pages11
JournalPublic Health
Volume123
Issue number8
DOIs
Publication statusPublished - 1 Aug 2009
Externally publishedYes

Fingerprint

Privatization
Malaysia
Pharmaceutical Preparations
Costs and Cost Analysis

Cite this

@article{23aae33978364d44873601cf707b95ed,
title = "Effect of privatization of the drug distribution system on drug prices in Malaysia",
abstract = "Background: Previous studies on anti-infective and cardiovascular drugs have shown extraordinary price increases following privatization of the Malaysian drug distribution system. Therefore, it was felt that there was a need to undertake a full-scale study to evaluate the effect of privatization of the Malaysian drug distribution system on drug prices. Objectives: To compare pre-privatization drug prices with post-privatization drug prices, and to compare the prices with international reference prices (IRPs). Methods: Five hundred and sixty-four drugs were listed in price lists for 1994, 1995-1996, 1997-2000 and 2001-2003. The 1994 data were taken as the pre-privatization prices, and all other lists were considered to be post-privatization prices. The pre-privatization prices (1994) were compared with those in 1995-1996. The prices in 1995-1996 were compared with those in 1997-2000, and the 1997-2000 prices were compared with those in 2001-2003. Furthermore, the 2001-2003 prices were compared with the median IRPs taken from Management Sciences for Health. Results: The prices increased by 10.42{\%} in 1995-1996, decreased by 3.37{\%} in 1997-2000, and increased by 64.04{\%} in 2001-2003. The increase in prices does not follow any pricing formula but is influenced by free market principles. The commonly used generic drugs showed enormously higher prices compared with the IRPs. Conclusion: Some of the prices increased several hundred-fold compared with the previous year, showing that no pricing formula has been followed. Increasing prices over the years may lead to higher expenditures and a hurdle to drug accessibility. A rational pricing structure is needed for transparent pricing, and government involvement and the formation of a medicine pricing policy seems vital.",
keywords = "Drug distribution system, Drug prices, International reference prices, Malaysia, Privatization",
author = "Babar, {Z. D.} and Izham, {M. I.M.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.puhe.2009.06.011",
language = "English",
volume = "123",
pages = "523--533",
journal = "Public Health",
issn = "0033-3506",
publisher = "Elsevier",
number = "8",

}

Effect of privatization of the drug distribution system on drug prices in Malaysia. / Babar, Z. D.; Izham, M. I.M.

In: Public Health, Vol. 123, No. 8, 01.08.2009, p. 523-533.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of privatization of the drug distribution system on drug prices in Malaysia

AU - Babar, Z. D.

AU - Izham, M. I.M.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Background: Previous studies on anti-infective and cardiovascular drugs have shown extraordinary price increases following privatization of the Malaysian drug distribution system. Therefore, it was felt that there was a need to undertake a full-scale study to evaluate the effect of privatization of the Malaysian drug distribution system on drug prices. Objectives: To compare pre-privatization drug prices with post-privatization drug prices, and to compare the prices with international reference prices (IRPs). Methods: Five hundred and sixty-four drugs were listed in price lists for 1994, 1995-1996, 1997-2000 and 2001-2003. The 1994 data were taken as the pre-privatization prices, and all other lists were considered to be post-privatization prices. The pre-privatization prices (1994) were compared with those in 1995-1996. The prices in 1995-1996 were compared with those in 1997-2000, and the 1997-2000 prices were compared with those in 2001-2003. Furthermore, the 2001-2003 prices were compared with the median IRPs taken from Management Sciences for Health. Results: The prices increased by 10.42% in 1995-1996, decreased by 3.37% in 1997-2000, and increased by 64.04% in 2001-2003. The increase in prices does not follow any pricing formula but is influenced by free market principles. The commonly used generic drugs showed enormously higher prices compared with the IRPs. Conclusion: Some of the prices increased several hundred-fold compared with the previous year, showing that no pricing formula has been followed. Increasing prices over the years may lead to higher expenditures and a hurdle to drug accessibility. A rational pricing structure is needed for transparent pricing, and government involvement and the formation of a medicine pricing policy seems vital.

AB - Background: Previous studies on anti-infective and cardiovascular drugs have shown extraordinary price increases following privatization of the Malaysian drug distribution system. Therefore, it was felt that there was a need to undertake a full-scale study to evaluate the effect of privatization of the Malaysian drug distribution system on drug prices. Objectives: To compare pre-privatization drug prices with post-privatization drug prices, and to compare the prices with international reference prices (IRPs). Methods: Five hundred and sixty-four drugs were listed in price lists for 1994, 1995-1996, 1997-2000 and 2001-2003. The 1994 data were taken as the pre-privatization prices, and all other lists were considered to be post-privatization prices. The pre-privatization prices (1994) were compared with those in 1995-1996. The prices in 1995-1996 were compared with those in 1997-2000, and the 1997-2000 prices were compared with those in 2001-2003. Furthermore, the 2001-2003 prices were compared with the median IRPs taken from Management Sciences for Health. Results: The prices increased by 10.42% in 1995-1996, decreased by 3.37% in 1997-2000, and increased by 64.04% in 2001-2003. The increase in prices does not follow any pricing formula but is influenced by free market principles. The commonly used generic drugs showed enormously higher prices compared with the IRPs. Conclusion: Some of the prices increased several hundred-fold compared with the previous year, showing that no pricing formula has been followed. Increasing prices over the years may lead to higher expenditures and a hurdle to drug accessibility. A rational pricing structure is needed for transparent pricing, and government involvement and the formation of a medicine pricing policy seems vital.

KW - Drug distribution system

KW - Drug prices

KW - International reference prices

KW - Malaysia

KW - Privatization

UR - http://www.scopus.com/inward/record.url?scp=69849104272&partnerID=8YFLogxK

U2 - 10.1016/j.puhe.2009.06.011

DO - 10.1016/j.puhe.2009.06.011

M3 - Article

VL - 123

SP - 523

EP - 533

JO - Public Health

JF - Public Health

SN - 0033-3506

IS - 8

ER -